Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Status:
Recruiting
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if certain drug combinations are effective treatments
for patients with advanced ER+/HER2- who have previously been treated with palbociclib,
ribociclib, or abemaciclib.